<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956940</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02911-54</org_study_id>
    <nct_id>NCT03956940</nct_id>
  </id_info>
  <brief_title>Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib</brief_title>
  <acronym>HELP</acronym>
  <official_title>A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to investigate whether quantitative analysis of the total
      concentration of circulating free deoxyribonucleic acid (cfDNA) and of the cfDNA integrity
      index (DII) (Intplex®) may reflect hepatocellular carcinoma (HCC) tumor dynamics or response
      for patients treated by Sorafenib or Regorafenib and if it could be used as a tool for
      patient management under targeted therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Circulating free deoxyribonucleic acid (cfDNA) is increasingly used in oncology with the aiml
      of early diagnosis of the disease, its therapeutic management and monitoring the evolution of
      the disease. Numerous publications have shown that the cfDNA concentration is correlated with
      the pathology of cancer. Larger amounts of cfDNA are detected in metastatic patients or
      patients with advanced cancer. However, the cfDNA concentrations have not yet shown their
      clinical interest mainly because of the variations in the same individual during the effort
      or the moment of collection of the blood sample. The concept of the integrity of cfDNA has
      also been studied as a biomarker in oncology and seems to show an interesting clinical value.
      The cfDNA is essentially released by cell apoptosis generating 170 bp fragments,
      corresponding to the size of a nucleosome. Many studies have shown that the integrity of
      cfDNA increases with the pathology of cancer. Thus, tumor-derived cfDNA is more fragmented
      than healthy cells with fragments smaller than the size nucleosome.

      To date, no predictive biomarker is available for the management of treatment with Sorafenib
      which is a targeted therapy with a marketing authorization in first-line treatment of HCC
      (hepatocellular carcinoma) or second line with Regorafenib, treatment having shown a benefit
      positive on overall survival in the Resorce study. AFP (alpha-foetoprotein) is the only serum
      marker available with an inconstant increase in patients with HCC in fact only 30 to 40% of
      patients have abnormal values. In liver cancer, Ono et al showed that serum cfDNA is
      positively correlated with a larger tumor size.

      This study shows that the rate of tumor cfDNA reflects the progression of the disease. Jiang
      et al showed that cfDNA derived from HCC is more fragmented than that derived from healthy
      cells, with fragments smaller than the size nucleosome.

      These data demonstrate the potential utility of cfDNA amount and integrity as a biomarker for
      individualized management of hepatocellular carcinoma.

      This new marker is expected to be an effective tool to overcome the lack of specificity of
      the AFP (alpha foetoprotein) assay in this pathology.

      The investigator's team developed an Intplex® test that showed significant discrimination
      between healthy individuals and cancer patients.

      The aim of this trial is to investigate whether quantitative analysis of the total
      concentration of cfDNA and of the cfDNA integrity index (DII) (Intplex®) may reflect HCC
      tumor dynamics or response for patients treated by Sorafenib or Regorafenib and if it could
      be used as a tool for patient management under targeted therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of total circulating free deoxyribonucleic acid (cfDNA) concentration at the baseline.</measure>
    <time_frame>Baseline</time_frame>
    <description>Total cfDNA concentration is considered as detected if total cfDNA concentration ≥ 5 ng/mL and not detected if total cfDNA concentration &lt; 5 ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total circulating free deoxyribonucleic acid (cfDNA) fragmentation index</measure>
    <time_frame>Baseline</time_frame>
    <description>Fragmentation of cfDNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From the date of inclusion to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>From the date of inclusion to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>The time from the date of start of Sorafenib (Regorafenib respectively) to the date of first documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>The time from the date of start of Sorafenib (Regorafenib respectively) to the date of first documented progression ( radiological or clinical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>The time from the date of start of Sorafenib to the date of documented death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hepatocarcinoma</condition>
  <arm_group>
    <arm_group_label>Intplex test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In vitro diagnostic device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intplex test</intervention_name>
    <description>Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks</description>
    <arm_group_label>Intplex test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients ≥ 18 years of age

          2. Histological or cytological documentation of hepatocellular carcinoma (HCC) or
             non-invasive diagnosis of HCC as per American Association for the Study of Liver
             Diseases (AASLD) criteria in patients with a confirmed diagnosis of cirrhosis

          3. Barcelona Clinical Liver Cancer (BCLC) stage Category B or C that cannot benefit from
             local treatments such as resection, local ablation, chemoembolization

          4. At least one uni-dimensional measurable lesion by computed tomography (CT) scan or
             magnetic resonance imaging (MRI) according to RECIST criteria 1.1 and modified RECIST
             for HCC

          5. Liver function status Child-Pugh Class A

          6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             tests:

               -  Hemoglobin &gt; 8.5 g/dL

               -  Absolute neutrophil count ≥ 1500/mm3

               -  Platelet count ≥ 60,000/ mm3

               -  Total bilirubin ≤ 2 mg/dL

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper
                  limit of normal (ULN)

               -  Serum creatinine ≤ 1.5 x Upper limit normal (ULN)

               -  Lipase ≤ 2 x ULN

               -  Prothrombin time-international normalized ratio (PT-INR) &lt; 2.3 x ULN and partial
                  thromboplastin time (PTT) &lt; 1.5 x ULN

               -  Glomerular Filtration Rate (GFR) ≥ 30 mL/min/1.73 m2

          8. Life expectancy ≥ 3 months

          9. Women of childbearing potential and men must agree to use adequate contraception

         10. Patients must be affiliated to a Social Security System

         11. Written informed consent signed

             Patients initially treated with Sorafenib, will be switched to Regorafenib if all the
             above conditions are still met and, in addition:

         12. Documented progression under treatment with Sorafenib (defined as documented
             radiological and/or clinical and/or biological progression)

        Exclusion Criteria:

          1. Prior liver transplantation or candidates for liver transplantation

          2. Hypersensitivity to the active substance or to any of the excipients

          3. Patients with large esophageal varices at risk of bleeding that are not being treated
             with conventional medical intervention

          4. Past or concurrent history of neoplasm other than HCC, except for in situ carcinoma of
             the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumors. Any
             cancer curatively treated &gt; 3 years prior to study entry is permitted

          5. Known history or symptomatic metastatic brain or meningeal tumors

          6. Major surgical procedure or significant traumatic injury within 28 days before
             enrollment

          7. Congestive heart failure New York Heart Association (NYHA) ≥ class 2

          8. Unstable angina or myocardial infarction within the past 6 months before enrollment

          9. Cardiac arrhythmias requiring anti-arrhythmic therapy

         10. Uncontrolled hypertension

         11. Patients with phaeochromocytoma

         12. Uncontrolled ascites

         13. Persistent proteinuria of NCI-CTCAE version 4.0 ≥ Grade 3

         14. Ongoing infection &gt; Grade 2 according to NCI-CTCAE version 4.0. Hepatitis B is allowed
             if no active replication is required

         15. Clinically significant bleeding NCI-CTCAE version 4.0 ≥ Grade 3 within 30 days before
             enrollment

         16. Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep
             vein thrombosis or pulmonary embolism within 6 months before enrollment

         17. Any psychological, familial, sociological, geographical or illness or medical
             condition that could jeopardize the safety of the patient and/or his compliance with
             the study protocol and follow-up procedure

         18. Known history of human immunodeficiency virus (HIV) infection

         19. Seizure disorder requiring medication

         20. Non-healing wound, ulcer or bone fracture

         21. Active autoimmune disease (lupus, sclerodermia, rheumatoid arthritis, …)

         22. Any malabsorption condition

         23. Breast feeding

         24. Pregnancy

         25. High performance sport practice

         26. Patient unable to swallow oral medication

        Patients who discontinue sorafenib will not be switched to regorafenib if any of the
        condition listed above occurs and/or the following criteria are met:

        27) Prior discontinuation of prior Sorafenib therapy due to Sorafenib-related toxicity 28)
        Unresolved toxicity (Sorafenib) ≥ NCI-CTCAE version 4.0 Grade 2

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric ASSENAT, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre BLEUSE, MD</last_name>
    <phone>0467613102</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Assénat, MD</last_name>
      <phone>467612593</phone>
      <phone_ext>+33</phone_ext>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Hôpital Michalon</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Decaens, MD</last_name>
      <phone>476766739</phone>
      <phone_ext>+33</phone_ext>
      <email>TDecaens@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann Touchefeu, MD</last_name>
      <phone>0240083152</phone>
      <phone_ext>+33</phone_ext>
      <email>yann.touchefeu@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy - Hôpital Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <state>Meurthe Et Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Bronowicki, MD</last_name>
      <phone>383153360</phone>
      <phone_ext>+33</phone_ext>
      <email>JP.bronowicki@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Duriez</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Mathurin, MD</last_name>
      <phone>320442097</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.mathurin@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <state>Seine-Saint-Denis</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Bouattour, MD</last_name>
      <phone>140874429</phone>
      <phone_ext>+33</phone_ext>
      <email>mohamed.bouattour@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. Review.</citation>
    <PMID>12834318</PMID>
  </reference>
  <reference>
    <citation>Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009 Dec 1;27(34):5734-42. doi: 10.1200/JCO.2009.23.1282. Epub 2009 Oct 5.</citation>
    <PMID>19805671</PMID>
  </reference>
  <reference>
    <citation>Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009 Jan 20;27(3):446-52. doi: 10.1200/JCO.2008.18.8151. Epub 2008 Dec 8.</citation>
    <PMID>19064965</PMID>
  </reference>
  <reference>
    <citation>Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5. doi: 10.1053/j.gastro.2012.05.052. Epub 2012 Jun 29.</citation>
    <PMID>22750200</PMID>
  </reference>
  <reference>
    <citation>Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012 Jul;57(1):101-7. doi: 10.1016/j.jhep.2012.02.016. Epub 2012 Mar 10.</citation>
    <PMID>22414760</PMID>
  </reference>
  <reference>
    <citation>Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, Tang ZY, Wang XW. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 2008 Mar 1;68(5):1451-61. doi: 10.1158/0008-5472.CAN-07-6013.</citation>
    <PMID>18316609</PMID>
  </reference>
  <reference>
    <citation>Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001 Jun 15;61(12):4675-8.</citation>
    <PMID>11406535</PMID>
  </reference>
  <reference>
    <citation>Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, Del Rio M, Lamy PJ, Bibeau F, Nouaille M, Loriot V, Jarrousse AS, Molina F, Mathonnet M, Pezet D, Ychou M. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014 Apr;20(4):430-5. doi: 10.1038/nm.3511. Epub 2014 Mar 23.</citation>
    <PMID>24658074</PMID>
  </reference>
  <reference>
    <citation>Thierry AR, El Messaoudi S, Gahan PB, Anker P, Stroun M. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 2016 Sep;35(3):347-76. doi: 10.1007/s10555-016-9629-x. Review.</citation>
    <PMID>27392603</PMID>
  </reference>
  <reference>
    <citation>Ono A, Fujimoto A, Yamamoto Y, Akamatsu S, Hiraga N, Imamura M, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Furuta M, Tsunoda T, Miyano S, Kubo M, Aikata H, Ochi H, Kawakami YI, Arihiro K, Ohdan H, Nakagawa H, Chayama K. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol. 2015 Jun 17;1(5):516-534. doi: 10.1016/j.jcmgh.2015.06.009. eCollection 2015 Sep.</citation>
    <PMID>28210698</PMID>
  </reference>
  <reference>
    <citation>Jiang P, Chan CW, Chan KC, Cheng SH, Wong J, Wong VW, Wong GL, Chan SL, Mok TS, Chan HL, Lai PB, Chiu RW, Lo YM. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1317-25. doi: 10.1073/pnas.1500076112. Epub 2015 Feb 2.</citation>
    <PMID>25646427</PMID>
  </reference>
  <reference>
    <citation>Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014 Feb 20;32(6):579-86. doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21. Review.</citation>
    <PMID>24449238</PMID>
  </reference>
  <reference>
    <citation>El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR. Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care. Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4.</citation>
    <PMID>26847055</PMID>
  </reference>
  <reference>
    <citation>Mouliere F, El Messaoudi S, Pang D, Dritschilo A, Thierry AR. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol. 2014 Jul;8(5):927-41. doi: 10.1016/j.molonc.2014.02.005. Epub 2014 Mar 24.</citation>
    <PMID>24698732</PMID>
  </reference>
  <reference>
    <citation>Zonta E, Nizard P, Taly V. Assessment of DNA Integrity, Applications for Cancer Research. Adv Clin Chem. 2015;70:197-246. doi: 10.1016/bs.acc.2015.03.002. Epub 2015 Apr 11. Review.</citation>
    <PMID>26231488</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocarcinoma</keyword>
  <keyword>cfDNA</keyword>
  <keyword>intplex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

